The breakthrough anticancer drug of Albright has been accepted by CDE!

On January 13, the latest announcement of CDE showed that venetoclax, a heavy drug owned by abbvie, had been listed in China, and three applications for listing had been accepted by CDE (acceptance No.: jxhs200002 / 3 / 4) Venetoclax is an oral B-cell lymphoma factor-2 (Bcl-2) inhibitor jointly developed by eberver / Roche gene tech it was first approved by FDA on April 11, 2016 It is the first drug for Bcl-2 approved by FDA and used to treat leukemia It has been awarded many breakthrough therapies by FDA Bcl-2 plays an important role in apoptosis and is the leading oncogene in most blood tumors Venclexta is a global first oral, selective B-cell lymphoma factor-2 (Bcl-2) inhibitor At present, the clinical trials approved by venetoclax in China include recurrent or refractory chronic lymphoblastic leukemia, acute myeloid leukemia and multiple myeloma with 17p deficiency Mengmeng's article is the integrated content of yaozhi.com, and the copyright belongs to the original author The purpose of reprint is to transmit more information, which does not represent the view of this platform If the content of the work, copyright and other issues are involved, please contact our website message, we will delete the content in the first time.